7PO Stock Overview
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Poxel S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.63 |
52 Week High | €0.83 |
52 Week Low | €0.20 |
Beta | 1.51 |
1 Month Change | -3.69% |
3 Month Change | 24.70% |
1 Year Change | -1.73% |
3 Year Change | -90.60% |
5 Year Change | -91.03% |
Change since IPO | -94.89% |
Recent News & Updates
Recent updates
Shareholder Returns
7PO | DE Biotechs | DE Market | |
---|---|---|---|
7D | -2.0% | -2.9% | 1.9% |
1Y | -1.7% | -25.4% | 5.9% |
Return vs Industry: 7PO exceeded the German Biotechs industry which returned -25.4% over the past year.
Return vs Market: 7PO underperformed the German Market which returned 5.9% over the past year.
Price Volatility
7PO volatility | |
---|---|
7PO Average Weekly Movement | 13.4% |
Biotechs Industry Average Movement | 5.2% |
Market Average Movement | 5.0% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7PO's share price has been volatile over the past 3 months.
Volatility Over Time: 7PO's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 15 | Thomas Kuhn | www.poxelpharma.com |
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company’s lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications.
Poxel S.A. Fundamentals Summary
7PO fundamental statistics | |
---|---|
Market cap | €25.77m |
Earnings (TTM) | -€44.24m |
Revenue (TTM) | €1.55m |
16.7x
P/S Ratio-0.6x
P/E RatioIs 7PO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
7PO income statement (TTM) | |
---|---|
Revenue | €1.55m |
Cost of Revenue | €1.54m |
Gross Profit | €2.00k |
Other Expenses | €44.24m |
Earnings | -€44.24m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
May 16, 2024
Earnings per share (EPS) | -1.14 |
Gross Margin | 0.13% |
Net Profit Margin | -2,861.58% |
Debt/Equity Ratio | -112.1% |
How did 7PO perform over the long term?
See historical performance and comparison